Please ensure Javascript is enabled for purposes of website accessibility

This Pharma Giant Lost the Vaccine Race, But Its COVID-19 Journey May Not Be Over

By Anirudh Shankar - Apr 27, 2021 at 6:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its vaccine might not have panned out as expected, but Merck has more in the works.

Pharmaceutical giant Merck (MRK 1.37%) has been relatively quiet during the COVID-19 pandemic. We saw a few of its peers, Johnson & Johnson and Pfizer, get their COVID-19 vaccines approved for mass manufacturing and commercial use, with governments from all over the world lining up to buy their jabs. However, Merck isn't out of the race yet; it, too, has COVID-19-related products in the pipeline. The combination of a booming pharmaceutical business and new products to help treat COVID-19 should tempt investors to pick up shares in this blue chip company

Two scientists in a lab examine a sample in a tube.

Image source: Getty Images.

A vaccine alternative

When the COVID-19 pandemic rocked the world, many major pharmaceutical companies scrambled to create a successful vaccine. Only a few have been successful thus far, and hundreds of millions of doses of COVID-19 vaccines have already been distributed. On Jan. 25, Merck discontinued the development of its COVID-19 vaccine. Instead, it plans to continue further development in its two investigational therapeutic candidates, including an antiviral pill that can treat patients with COVID-19.

The antiviral drug, molnupiravir, is still in clinical trials for early use in coronavirus disease progression. So far, it's failed to significantly help hospitalized patients. If further testing is done and the treatment is shown to be successful as an early treatment, it would give doctors an important new weapon against coronaviruses and future illnesses. Merck licensed the pill from Ridgeback Biotherapeutics last July. The company expects molnupiravir's clinical trials to end sometime between September and October of this year.

COVID outlook

In a press release on March 10, Merck announced a partnership with Johnson & Johnson to expand manufacturing capacity and help increase supply of Johnson & Johnson's COVID-19 vaccine. Merck will be upgrading their existing manufacturing plants to accelerate the production of the vaccine. 

On top of molnupiravir and vaccine partnerships, Merck spent $425 million to buy OncoImmune, a company that was developing treatments for immune modification that benefited patients hospitalized with COVID-19. As a part of that acquisition, which was completed in December 2020, Merck brought MK-7110, a potential treatment for COVID, into its portfolio.

On that front, however, there have been more setbacks for Merck. Its development of the MK-7110 came to a permanent halt this month, after the company weighed the costs and benefits of continuing trials for the treatment. This was in response to the U.S. Food and Drug Administration (FDA) requests for additional data as well as the need for increasing approvals for manufacturing this therapeutic at scale. In an April 15 press release, the company said it looked forward to focusing "its pandemic efforts on advancing molnupiravir and on producing Johnson & Johnson’s COVID-19 vaccine."

A booming business otherwise

Outside of COVID-19, Merck's business has been thriving in recent years. Earnings growth has been fueled by its flagship drug, Keytruda, which is approved to treat various cancer indications, and won over $14 billion in sales last year. Outside of Keytruda, the company has seen its other drugs growing in terms of revenue, including Gardasil, Bridion, and Pneumovax 23. These drugs have seen annual sales growth of 5.37%, 5.92%, and 14.8% respectively.

AbbVie's Humira still holds the spot for the best-selling drug in the world, but Keytruda is projected to claim its place in the not too distant future. Humira brought in over $20 billion in sales in 2020, but due to concerns over patents, which will begin to expire in 2023, I think that Keytruda is all set to shine.

A great time to buy

In the last few years, Merck has traded at a price-to-earnings (P/E) multiple around 15 or 16. However, Merck is now trading at a valuation of just under 12. If we were to apply a 15 P/E to the fiscal year 2020's earnings per share, we would get a stock price of around $98. This would represent a 27% potential upside from the current share price of $77. If molnupiravir is a success and emergency authorization or approval comes from the FDA, it will make the case even stronger for a Merck purchase at these levels. 

Merck is a quintessential blue-chip pharmaceutical company and currently offers a 3.25% dividend yield to investors. The company recently increased the dividend by 11%, and although it doesn't have a regular history of increases, Merck could be poised to make dividend boosts the new normal in order to reward shareholders. For all of these reasons, investors may want to consider this stock for the long term.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.42 (1.37%) $1.25
Pfizer Inc. Stock Quote
Pfizer Inc.
$52.31 (-0.23%) $0.12
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.52 (1.13%) $2.01
AbbVie Inc. Stock Quote
AbbVie Inc.
$153.80 (0.42%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.